Editorial Perspectives On Patient Recruitment

  1. When Survival Comes First, Trials Come Last 8/1/2025

    Infectious disease PI Dr. Claudia Martorell has long focused on recruiting underserved populations into clinical trials. But amid healthcare cuts, economic instability, and a retreat from DEI initiatives, she’s now watching access unravel. In this interview, Martorell shares what happens when survival takes priority over research — and why diversity in trials is once again at risk.

  2. PI's CRAACO Model + AI = Rapid Enrollment 6/30/2025

    At Dr. David Almeida’s clinical trial site in Erie, PA, he practices the CRAACO model exclusively, relying on the revenue he makes from conducting clinical trials for eye-related diseases. To minimize his costs and speed up trial enrollment, he uses a proprietary AI system that has given him an 85% screen-to-enroll ratio.

  3. Takeda's Diversity Strategy Pays Off For Phase 3 Trial 3/12/2025

    LaShell Robinson, head of global feasibility and trial equity at Takeda explains how the company’s Phase 3 trial for a psoriasis drug ended enrollment well before it’s goal and achieved some impressive diversity metrics. 

  4. The Scoop On SCOPE 2/7/2025

    Chief Editor Dan Schell summarizes some of his favorite quotes and learnings from the 2025 SCOPE Summit. Spoiler alert … Not everything is about AI these days. 

  5. We're Looking At Patient Recruitment All Wrong 1/22/2025

    Leanne Woehlke, a 30-year veteran of the clinical research industry, says our standard patient recruitment efforts are lacking one key element — a focus on the patient’s needs. 

  6. Let's Fix The Tax Burden On Clinical Trial Participants 12/10/2024

    We all know that patient retention is lowered once a participant realizes the tax implications of being in a clinical trial. But taxes should be the last thing they have to worry about, so why can’t we get some changes made? 

  7. 2024: Familiar Problems & Encouraging Progress 11/27/2024

    For part 1 of my 2024 recap, I asked various industry experts what stood out to them this year regarding the clinical trials industry. They mentioned significant challenges related to site capacity, enrollment, workforce changes, and trial complexity, but they also seemed encouraged with some of the efforts and emerging solutions that will address these issues.

  8. Not A Bad First Year 11/11/2024

    Dan Schell, chief Editor or Clinical Leader, summarizes his first year in this role and highlights some of his key takeaways and lists some of the people who have helped him better understand the clinical trials ecosystem. 

  9. Key Takeaways From Clinical Trial Diversity Discussion 9/24/2024

    During the Clinical Leader Live, The Diversity Mandate: Effective Strategies in Clinical Trials”, we discussed everything from the guidance, to diversity action plans, to the need for better data on race, ethnicity, and identity. In this article, we also share 25 questions audience members had regarding this hot topic.

  10. Government Contract Advances Walgreens In Clinical Space 8/1/2024

    Walgreen’s new $25 million deal with BARDA (Biomedical Advanced Research and Development Authority) is a huge win for the pharmacy chain. John Campbell, head of DCTs at Walgreens, explains the ins and outs of the study and what could be next for the company regarding its clinical trials division.